Ardelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary

Ardelyx

06/08/2026 23:23

Ardelyx, Inc. ARDX.OQ reported a quarterly adjusted loss of 7 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -8 cents.  The mean expectation of eleven analysts for the quarter was for a loss of 6 cents per share. Wall Street expected results to range from -9 cents to -3 cents per share.
Revenue rose 23.8% to $120.88 million from a year ago; analysts expected $121.01 million. 
Ardelyx, Inc.'s reported EPS for the quarter was a loss of 7 cents​.
The company reported a quarterly loss of $16.72 million.
Ardelyx, Inc. shares had fallen by 3.7% this quarter and lost 15.8% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 66.2% in the last three months.​ 
In the last 30 days, five analysts negatively revised earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Ardelyx, Inc. is $16.00, about 69.6% above its last closing price of $4.87
This summary was machine generated from LSEG data August 6 at 10:23 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.06
-0.07
Missed
Mar. 31 2026 
-0.14
-0.15
Missed
Dec. 31 2025 
0.01
0.00
Missed
Sep. 30 2025 
-0.06
0.00
Beat